Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
Company profile
Ticker
AIMT
Exchange
Website
CEO
Jayson Donald Alexander Dallas
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Allergen Research Corp
SEC CIK
Corporate docs
Subsidiaries
Aimmune Therapeutics UK Limited • Aimmune Therapeutics (Bermuda) Ltd. • Aimmune Therapeutics Netherlands B.V. • Aimmune Therapeutics Ireland Limited • Aimmune Therapeutics Germany GmbH ...
AIMT stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
23 Oct 20
8-K
Termination of a Material Definitive Agreement
19 Oct 20
EFFECT
Notice of effectiveness
15 Oct 20
EFFECT
Notice of effectiveness
15 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
POS AM
Prospectus update (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 20
Latest ownership filings
SC 13G/A
Palo Alto Investors LP
16 Feb 21
4
Change in insider ownership
15 Oct 20
4
Andrew Oxtoby
14 Oct 20
4
Douglas T. Sheehy
14 Oct 20
4
Jayson Donald Alexander Dallas
14 Oct 20
4
MARK MCDADE
14 Oct 20
4
Gregory Behar
14 Oct 20
4
BRETT K HAUMANN
14 Oct 20
4
Stacey Denenberg Seltzer
14 Oct 20
4
ERIC BJERKHOLT
14 Oct 20
Financial summary
Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 266.56 mm | 266.56 mm | 266.56 mm | 266.56 mm | 266.56 mm | 266.56 mm |
Cash burn (monthly) | 10.62 mm | (no burn) | 22.97 mm | 23.59 mm | 18.37 mm | 18.66 mm |
Cash used (since last report) | 486.77 mm | n/a | 1.05 bn | 1.08 bn | 841.99 mm | 855.38 mm |
Cash remaining | -220.21 mm | n/a | -786.51 mm | -814.52 mm | -575.43 mm | -588.82 mm |
Runway (months of cash) | -20.7 | n/a | -34.2 | -34.5 | -31.3 | -31.6 |
Institutional ownership, Q1 2023
28.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 18.74 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Nestle Health Science US | 12.73 mm | $0.00 |
Longitude Capital Partners II | 6.01 mm | $0.00 |
Societe des Produits Nestle | 100.00 | $0.00 |